Gain Therapeutics, Inc.
GANX
$1.65
-$0.04-2.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -5.42% | -24.17% | -24.68% | 40.16% | 38.19% |
| Gross Profit | 5.42% | 24.17% | 24.68% | -40.16% | -39.19% |
| SG&A Expenses | -10.82% | -10.26% | -16.89% | -2.81% | -10.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.00% | -17.92% | -21.02% | -4.91% | -8.74% |
| Operating Income | 8.00% | 17.92% | 21.02% | 4.91% | 8.51% |
| Income Before Tax | 2.89% | 15.12% | 17.21% | 3.57% | 10.43% |
| Income Tax Expenses | 60.41% | 2,680.47% | 1,226.44% | 648.36% | 576.92% |
| Earnings from Continuing Operations | 1.22% | 9.24% | 13.92% | 1.03% | 8.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.22% | 9.24% | 13.92% | 1.03% | 8.34% |
| EBIT | 8.00% | 17.92% | 21.02% | 4.91% | 8.51% |
| EBITDA | 8.05% | 17.95% | 21.06% | 4.92% | 8.53% |
| EPS Basic | 34.85% | 43.72% | 50.90% | 42.04% | 45.18% |
| Normalized Basic EPS | 36.21% | 47.31% | 52.78% | 43.28% | 46.14% |
| EPS Diluted | 34.85% | 43.72% | 50.90% | 42.04% | 45.18% |
| Normalized Diluted EPS | 36.21% | 47.31% | 52.78% | 43.28% | 46.14% |
| Average Basic Shares Outstanding | 44.20% | 54.59% | 74.48% | 75.84% | 75.68% |
| Average Diluted Shares Outstanding | 44.20% | 54.59% | 74.48% | 75.84% | 75.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |